{"id":"https://openalex.org/W1608070229","doi":null,"title":"Alogliptin for treatment of type 2 diabetes","display_name":"Alogliptin for treatment of type 2 diabetes","publication_year":2014,"publication_date":"2014-02-18","ids":{"openalex":"https://openalex.org/W1608070229","mag":"1608070229"},"language":"en","primary_location":{"id":"mag:1608070229","doi":null,"is_oa":false,"landing_page_url":"https://www.researchgate.net/profile/Yoshifumi_Saisho/publication/260285890_Alogliptin_for_treatment_of_type_2_diabetes/links/53edf34b0cf23733e80b1c3b.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S2764672440","display_name":"Journal of symptoms and signs","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Journal of symptoms and signs","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013836607","display_name":"Yoshifumi Saisho","orcid":"https://orcid.org/0000-0002-6071-4393","observed_orcids":["https://orcid.org/0000-0002-6071-4393"]},"institutions":[{"id":"https://openalex.org/I203951103","display_name":"Keio University","ror":"https://ror.org/02kn6nx58","country_code":"JP","type":"education","lineage":["https://openalex.org/I203951103"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Yoshifumi Saisho","raw_affiliation_strings":["Keio Univ"],"raw_orcid":"https://orcid.org/0000-0002-6071-4393","affiliations":[{"raw_affiliation_string":"Keio Univ","institution_ids":["https://openalex.org/I203951103"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5013836607"],"corresponding_institution_ids":["https://openalex.org/I203951103"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"3","issue":"1","first_page":"26","last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11140","display_name":"Natural Antidiabetic Agents Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alogliptin","display_name":"alogliptin","score":0.996999979019165},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9359999895095825},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9900000095367432},{"id":"https://openalex.org/keywords/incretin-hormones","display_name":"incretins","score":0.6359999775886536},{"id":"https://openalex.org/keywords/glucose-dependent-insulin-secretion","display_name":"glucose-dependent insulin secretion","score":0.9399999976158142},{"id":"https://openalex.org/keywords/beta-cell-function","display_name":"beta-cell function","score":0.8370000123977661},{"id":"https://openalex.org/keywords/oral-antidiabetic-drugs","display_name":"oral antidiabetic drugs","score":0.9409999847412109},{"id":"https://openalex.org/keywords/hypoglycemia-risk","display_name":"hypoglycemia risk","score":0.9039999842643738},{"id":"https://openalex.org/keywords/cardiovascular-safety","display_name":"cardiovascular safety","score":0.800000011920929},{"id":"https://openalex.org/keywords/drug-efficacy-and-safety","display_name":"drug safety and efficacy","score":0.859000027179718}],"concepts":[{"id":"https://openalex.org/C2780012697","wikidata":"https://www.wikidata.org/wiki/Q4734170","display_name":"Alogliptin","level":5,"score":0.9880771636962891},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7843239307403564},{"id":"https://openalex.org/C2778881409","wikidata":"https://www.wikidata.org/wiki/Q1420402","display_name":"Incretin","level":4,"score":0.7771831154823303},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.6816293001174927},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.599533200263977},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5738477110862732},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5728572010993958},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.5500593781471252},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.43404003977775574},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3887009620666504},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3100120425224304}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:1608070229","doi":null,"is_oa":false,"landing_page_url":"https://www.researchgate.net/profile/Yoshifumi_Saisho/publication/260285890_Alogliptin_for_treatment_of_type_2_diabetes/links/53edf34b0cf23733e80b1c3b.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S2764672440","display_name":"Journal of symptoms and signs","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Journal of symptoms and signs","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":62,"referenced_works":["https://openalex.org/W20782350","https://openalex.org/W73823178","https://openalex.org/W1569365382","https://openalex.org/W1967096313","https://openalex.org/W1983379669","https://openalex.org/W1986044732","https://openalex.org/W1998401806","https://openalex.org/W1998735190","https://openalex.org/W2001031720","https://openalex.org/W2001270128","https://openalex.org/W2005404676","https://openalex.org/W2005754586","https://openalex.org/W2006464901","https://openalex.org/W2016632734","https://openalex.org/W2027788348","https://openalex.org/W2031848004","https://openalex.org/W2042362312","https://openalex.org/W2045505493","https://openalex.org/W2047730645","https://openalex.org/W2055872273","https://openalex.org/W2059245135","https://openalex.org/W2059903872","https://openalex.org/W2061865937","https://openalex.org/W2064780710","https://openalex.org/W2066598812","https://openalex.org/W2067663978","https://openalex.org/W2067736115","https://openalex.org/W2069702606","https://openalex.org/W2072402715","https://openalex.org/W2074881344","https://openalex.org/W2077149049","https://openalex.org/W2078923086","https://openalex.org/W2084403835","https://openalex.org/W2086842286","https://openalex.org/W2086855138","https://openalex.org/W2090582239","https://openalex.org/W2092287139","https://openalex.org/W2092918268","https://openalex.org/W2094625675","https://openalex.org/W2100271953","https://openalex.org/W2104288577","https://openalex.org/W2106154942","https://openalex.org/W2113544353","https://openalex.org/W2118267307","https://openalex.org/W2118830784","https://openalex.org/W2121879147","https://openalex.org/W2124701241","https://openalex.org/W2125653714","https://openalex.org/W2127825630","https://openalex.org/W2127854619","https://openalex.org/W2128357880","https://openalex.org/W2129248887","https://openalex.org/W2136090804","https://openalex.org/W2140986962","https://openalex.org/W2141946042","https://openalex.org/W2142361019","https://openalex.org/W2147743786","https://openalex.org/W2151668968","https://openalex.org/W2151848850","https://openalex.org/W2158572298","https://openalex.org/W2160327592","https://openalex.org/W2168626372"],"related_works":["https://openalex.org/W7036245053","https://openalex.org/W2160327592","https://openalex.org/W2111110328","https://openalex.org/W2044584051","https://openalex.org/W2136619394","https://openalex.org/W2023930489","https://openalex.org/W2279665455","https://openalex.org/W2981524043","https://openalex.org/W2082354988","https://openalex.org/W2127608460"],"abstract_inverted_index":{"Dipeptidyl":[0],"peptidase-4":[1],"(DPP-4)":[2],"inhibitors,":[3,97],"a":[4,24,54,65,77,85,115],"new":[5],"class":[6],"of":[7,17,27,35,39,57,68,70,94,101,108,126,132,138,183,189],"oral":[8],"hypoglycemic":[9],"agents,":[10],"augment":[11],"glucose-dependent":[12],"insulin":[13],"secretion":[14],"through":[15],"enhancement":[16],"endogenous":[18],"incretin":[19],"action":[20],"by":[21],"inhibiting":[22],"DPP-4,":[23],"degrading":[25],"enzyme":[26],"incretin.":[28],"DPP-4":[29,61,81,96,133,146],"inhibitors":[30,62,134],"are":[31,63],"generally":[32],"well-tolerated":[33],"because":[34],"their":[36,47],"low":[37,99],"risk":[38,100],"hypoglycemia":[40,102],"and":[41,103,124,128],"other":[42,95],"adverse":[43],"events.":[44],"Moreover,":[45],"with":[46,98],"potential":[48],"to":[49,92],"improve":[50],"beta":[51],"cell":[52],"function,":[53],"core":[55],"defect":[56],"type":[58,71,139,148],"2":[59,72,140,149],"diabetes,":[60],"becoming":[64],"major":[66],"component":[67],"treatment":[69,137],"diabetes.":[73,141],"Alogliptin":[74],"benzoate":[75],"is":[76,90],"newly-developed,":[78],"highly":[79],"selective":[80],"inhibitor.":[82],"It":[83],"has":[84,111],"potent":[86],"glucose-lowering":[87],"effect":[88],"which":[89],"similar":[91],"that":[93],"weight":[104],"gain.":[105],"Cardiovascular":[106],"safety":[107,125],"this":[109],"drug":[110],"been":[112],"confirmed":[113],"in":[114,135],"recent":[116],"large-scale":[117],"trial.":[118],"This":[119],"minireview":[120],"summarizes":[121],"the":[122,130,136],"efficacy":[123],"alogliptin,":[127],"discusses":[129],"role":[131],"Keywords:":[144],"inhibitor;":[147],"diabetes;":[150],"efficacy;":[151],"safety;":[152],"alogliptin.":[153],"Received:":[156],"October":[158],"1,":[159],"2013;":[160,166],"Accepted:":[162],"December":[164],"24,":[165],"Published:":[168],"February":[170],"18,":[171],"2014":[172],"Corresponding":[175],"Author:":[176],"Yoshifumi":[178],"Saisho,":[179],"MD,":[180],"PhD,":[181],"Department":[182],"Internal":[184],"Medicine,":[185,190],"Keio":[186],"University":[187],"School":[188],"35":[191],"Shinanomachi,":[192],"Shinjuku-ku,":[193],"Tokyo":[194],"160-8582,":[195],"Japan":[196],".":[197,202],"E-mail:":[198],"ysaisho@z5.keio.jp":[201]},"counts_by_year":[],"updated_date":"2025-10-10T17:16:08.811792","created_date":"2016-06-24T00:00:00"}